+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market for Active Pharmaceutical Ingredients in China - Forecast and Analysis 2018

  • PDF Icon

    Report

  • 160 Pages
  • October 2018
  • Region: China
  • Aruvian Research
  • ID: 4629843

In recent years, China has emerged as the second biggest pharmaceutical market in the world. It is today one of the fastest emerging markets in the pharmaceutical and biotechnology sector globally. A rapidly-ageing population along with a thriving middle class has opened up this market for tremendous opportunities for active pharmaceutical ingredients (APIs) sector. With the Chinese government setting its sights on becoming an important innovator of a variety of pharmaceutical products.

The market for active pharmaceutical ingredients in China is the second largest API market in the entire Asia Pacific region, second only to Japan. In 2017 alone, China accounted for over 20% of the revenues for the Asia Pacific API industry. With many national pharmaceutical companies dominating the domestic pharmaceutical industry, the Chinese market has recently witnessed the entry of many large foreign pharmaceutical companies setting up their plants in the country. However, China faces a major issue with intellectual property rights protection, which has resulted in a low level of market penetration for branded drugs, allowing generics to dominate the domestic market.

With the government determined to tighten regulations governing intellectual property rights, it is expected that the market for APIs in China is going to witness a major boost in the coming years.

This research analyzes the market for APIs in China in its research report Market for Active Pharmaceutical Ingredients in China – Forecast and Analysis 2018. The data covered in this report ranges from 2008 till 2020. Let us take a look at what the report focusses on.

The report begins with an introduction to Active Pharmaceutical Ingredients and then moves on to briefly analyze the global market for active pharmaceutical ingredients. We include an overview of the global market for APIs and a look at the global market's revenues.

Section D of the report analyzes the market for active pharmaceutical ingredients in Asia Pacific through an industry overview, industry revenues, and a look at the various therapeutic applications of APIs in the Asia Pacific region. Impacts on the Asia Pacific active pharmaceutical ingredients market are also analyzed.

With section E, we begin our analysis of the market for active pharmaceutical ingredients in China. This section analyzes the industry through basic statistics and industry revenues. Industry segmentation through the biotech segment and the synthetic API market in China is included in the report, along with a forecast of the industry till 2020.

An analysis of the major industry players, both global and domestic, are included in the report. The major players are analyzed through a business segment profile, a look at their major products and services, and a SWOT analysis. The analysis looks at nearly 25 major companies operating in the Chinese API market.

Research methodology for the report concludes this comprehensive report on the market for active pharmaceutical ingredients in China till 2020.

Table of Contents


A. Executive SummaryB. Introduction to Active Pharmaceutical Ingredients
C. Global Market for Active Pharmaceutical Ingredients (APIs)
C.1 Industry Overview
C.2 Industry Revenues
D. Market for Active Pharmaceutical Ingredients (APIs) in Asia Pacific
D.1 Industry Overview
D.2 Industry Revenues
D.3 Therapeutic Applications of API in Asia Pacific
D.4 Impacts on the Industry
E. Market for Active Pharmaceutical Ingredients (APIs) in China
E.1 Industry Overview
E.2 Industry Revenues
F. API Market in China: Industry Segmentation
F.1 Overview
F.2 Biotech API Market in China
F.3 Synthetic API Market in China
G. Major Industry Players
G.1 Albemarle Corporation
G.1.1 Business Profile
G.1.2 Major Products & Services
G.1.3 SWOT Analysis
G.2 Allergan Plc
G.2.1 Business Profile
G.2.2 Major Products & Services
G.2.3 SWOT Analysis
G.3 BASF SE
G.3.1 Business Profile
G.3.2 Major Products & Services
G.3.3 SWOT Analysis
G.4 Boehringer Ingelheim GmbH
G.4.1 Business Profile
G.4.2 Major Products & Services
G.4.3 SWOT Analysis
G.5 Bristol-Myers Squibb Company
G.5.1 Business Profile
G.5.2 Major Products & Services
G.5.3 SWOT Analysis
G.6 Koninklijke DSM N.V.
G.6.1 Business Profile
G.6.2 Major Products & Services
G.6.3 SWOT Analysis
G.7 Lonza Group AG
G.7.1 Business Profile
G.7.2 Major Products & Services
G.7.3 SWOT Analysis
G.8 Novartis AG
G.8.1 Business Profile
G.8.2 Major Products & Services
G.8.3 SWOT Analysis
G.9 Pfizer Inc.
G.9.1 Business Profile
G.9.2 Major Products & Services
G.9.3 SWOT Analysis
G.10 Sigma-Aldrich Corporation
G.10.1 Business Profile
G.10.2 Major Products & Services
G.10.3 SWOT Analysis
G.11 Teva Pharmaceutical Industries Limited
G.11.1 Business Profile
G.11.2 Major Products & Services
G.11.3 SWOT Analysis
G.12 Aurobindo Pharma
G.13 Cheng Fong Chemical Co. Ltd
G.14 China Grand Pharmaceutical and Healthcare Holdings Limited
G.15 China National Pharmaceutical Group (Sinopharm)
G.16 CSPC Zhongrun Pharmaceutical Co. Ltd. (Hebei Zhongrun)
G.17 Guangzhou Pharmaceutical Holdings Limited
G.18 Harbin Pharmaceutical Group
G.19 Hebei Yuxing Bio-Engineering Co Ltd
G.20 Medtronic Plc
G.21 Nanjing Ange Pharmaceutical
G.22 Shijiazhuang Pharma Group
G.23 WuXi AppTec, Inc
H. Glossary of TermsI. Research Methodology
List of Figures
Figure 1: Revenues of the Global Active Pharmaceutical Ingredient (API) Market (in USD Million), 2008-2020
Figure 2: Revenues of the Active Pharmaceutical Ingredient (API) Market in Asia Pacific (in USD Million), 2008-2020
Figure 3: Revenue Breakdown of the API Market in Asia Pacific by Therapeutic Applications (%), 2017 & 2020
Figure 4: Revenues of the Active Pharmaceutical Ingredient (API) Market in China (in USD Million), 2008-2020
Figure 5: China API Industry Segmentation by Revenues (%), 2008-2020
Figure 6: Revenues of the Biotech API Market in China by Application Sector (in USD Million), 2008-2020
Figure 7: Share of China Biotech API Market by Application Sector (%), 2008-2020
Figure 8: Revenues of the Synthetic API Market in China by Application Sector (in USD Million), 2008-2020
Figure 9: Share of the Synthetic API Market in China by Application Sector (%), 2008-2020
List of Tables
Table 1: Revenues of the Global Active Pharmaceutical Ingredient (API) Market (in USD Million), 2008-2020
Table 2: Revenues of the Active Pharmaceutical Ingredient (API) Market in Asia Pacific (in USD Million), 2008-2020
Table 3: Revenue Breakdown of the API Market in Asia Pacific by Therapeutic Applications (%), 2017 & 2020
Table 4: Revenues of the Active Pharmaceutical Ingredient (API) Market in China (in USD Million), 2008-2020
Table 5: Revenues of the Biotech API Market in China by Application Sector (in USD Million), 2008-2020
Table 6: Revenues of the Synthetic API Market in China by Application Sector (in USD Million), 2008-2020

Companies Mentioned

  • Albemarle Corporation
  • Allergan Plc
  • Aurobindo Pharma
  • BASF SE
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cheng Fong Chemical Co. Ltd
  • China Grand Pharmaceutical and Healthcare Holdings Limited
  • China National Pharmaceutical Group (Sinopharm)
  • CSPC Zhongrun Pharmaceutical Co. Ltd. (Hebei Zhongrun)
  • Guangzhou Pharmaceutical Holdings Limited
  • Harbin Pharmaceutical Group
  • Hebei Yuxing Bio-Engineering Co Ltd
  • Koninklijke DSM N.V.
  • Lonza Group AG
  • Medtronic Plc
  • Nanjing Ange Pharmaceutical
  • Novartis AG
  • Pfizer Inc.
  • Shijiazhuang Pharma Group
  • Sigma-Aldrich Corporation
  • Teva Pharmaceutical Industries Limited
  • WuXi AppTec, Inc